SPRY - ARS Pharmaceuticals, Inc.
IEX Last Trade
11.05
-0.180 -1.629%
Share volume: 344
Last Updated: Thu 26 Dec 2024 03:30:25 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$11.23
-0.18
-1.60%
Fundamental analysis
24%
Profitability
25%
Dept financing
1%
Liquidity
75%
Performance
15%
Performance
5 Days
2.06%
1 Month
-16.78%
3 Months
-18.79%
6 Months
49.15%
1 Year
121.12%
2 Year
41.21%
Key data
Stock price
$11.05
DAY RANGE
$11.14 - $11.23
52 WEEK RANGE
$5.59 - $18.51
52 WEEK CHANGE
$102.30
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Richard E. Lowenthal
Region: US
Website: ars-pharma.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ars-pharma.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Recent news